New TAVR system for pure aortic regurgitation used for first time, linked to ‘excellent’ short-term outcomes

The Pioneer TAVR system from KOKA Lifesciences

Image courtesy of Guo et al. and JACC: Cardiovascular Interventions.

Researchers explored data from the first 10 patients treated with a new self-expanding TAVR device from KOKA Lifesciences. After 30 days, there were no patient deaths and only one adverse event.